Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Advocacy » Australasian Gastro-Intestinal Trials Group (AGITG) ASM

Australasian Gastro-Intestinal Trials Group (AGITG) ASM

  • November 26, 2018

AGITG Annual Scientific Meeting – Brisbane
Convention Centre  31 Oct- 2
Nov 2018

(Written by
Meredith Cummins)


The AGITG ASM
was well attended by over 300 Health Professionals from Australia and New
Zealand. As per previous years this is truly a multidisciplinary meeting which
provides updates on current research and trials for gastrointestinal cancers
and provides a wonderful opportunity to network with national and international
leaders in this field.

Unicorn Foundation CEO Simone Leyden presented data from the INCA/Novartis global survey alongside our recent PET reimbursement survey and Financial Toxicity survey. Please note that the Financial Toxicity survey is still open and we would love to receive more responses to gain greater insight into this area (see below for Simone's slide presentation)

The Unicorn
Foundation (UF) had a booth which enabled health professionals to gain access
to information and dietary booklets and meet with UF staff to discuss projects
currently in progress and future directions in education and collaboration.
Many clinicians also signed up for the Healthcare Professionals eNewsletters as
the awareness of Neuroendocrine Tumours (NETs) increases.

The Unicorn
Foundation submitted a poster for the PLANET Registry which gained much
interest from the attendees at the meeting. Within the program were updates on
the Unicorn Foundation funded clinical trial CONTROL NETs (Capecitabine, Temozolomide & PRRT vs
Capecitabine & Temozolomide vs PRRT) which has reached its recruitment target,
NABNEC (A
Randomised Phase II Study Of Nab-paclitaxel In Combination With Carboplatin As
First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
) which is also studying
tumour cells in detail to understand more about the biology of the tumour
cells, why tumours can have such different outcomes in different patients and
why some tumours become resistant to drugs.
NABNEC is currently
recruiting till the latter part of 2019. Simone Leyden presented in the Joint
Consumer / Study Coordinators forum on the afternoon of 1 November. The topic
presented was “Financial Toxicity” which is surveying NET consumers nationally.
The Principal Investigator for this survey is Dr David Wyld and it is being
coordinated by the University of Brisbane and the Unicorn Foundation nationally.
Recruitment for this survey will be completed by the end of November.

There are
increasing areas of Research and Clinical Trials being conducted, of which the
Unicorn Foundation is very active in providing valuable funding to enable this
to improve the care and the outcomes for NET patients.

                                   

Share this post

Recent posts

International Nurses Day 2025

May 12, 2025

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousA penny for your thoughts
NextNET Patient SymposiumNext

Related Posts

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

NeuroEndocrine Cancer Australia (NECA) is proud to be the voice for thousands of Australians living with Neuroendocrine Cancer (NETs). But to do more — reach

Parliament House representation for Federal Budget briefings

NECA attends the Treasurer’s Speech at Parliament House and then Medicines Australia Patient Organisation Brief at the Press Club on Wednesday 26 March 2025. The

VHL in the news March 2025

Read the Magazine copy here.

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin